Quick answer: Most patients receive laboratory results as a series of numbers with “H” or “L” flags and “normal range” columns — but the standard reference ranges are statistical constructs based on the middle 95% of a tested population, not evidence-based thresholds for optimal health. Functional medicine interprets labs in clinical context, uses tighter “optimal” ranges derived from outcomes research, and looks for patterns across multiple markers that tell a more complete story than any single value.
The Problem with “Normal” Reference Ranges
Understanding how laboratory reference ranges are established is foundational to interpreting them intelligently. Most reference ranges are calculated as the mean ± 2 standard deviations of a “healthy” reference population — meaning by statistical definition, 2.5% of truly healthy people will fall outside the normal range on any given test, and 2.5% of genuinely pathological results will appear “normal.” With a standard metabolic panel of 14 tests ordered simultaneously, the probability that at least one result falls outside reference range purely by chance is 1 – (0.95)^14 = 51.2%.
More critically, “healthy population” is loosely defined — reference populations often include individuals with undiagnosed metabolic syndrome, insulin resistance, nutritional deficiencies, and early chronic disease. The “normal” TSH range of 0.5-4.5 mIU/L was established from a population that included undiagnosed Hashimoto’s patients with elevated TSH — artificially widening the upper end. Functional medicine uses outcomes-based reference ranges — where does the evidence show increased disease risk, and where does clinical physiology function optimally?
The Complete Metabolic Panel: Functional Interpretation
Glucose (fasting): Standard reference range: 70-100 mg/dL. Functional medicine optimal: 70-85 mg/dL. The American Diabetes Association’s “pre-diabetes” threshold of 100-125 mg/dL encompasses a huge clinical opportunity — this is the window where lifestyle intervention is most effective. The Diabetes Prevention Program demonstrated 58% reduction in diabetes progression with lifestyle intervention in this range. Functional medicine begins aggressive intervention at fasting glucose >90 mg/dL, not 126 mg/dL (the diabetes diagnosis threshold).
Hemoglobin A1c (HbA1c): Reflects 3-month average blood glucose. Standard “normal” <5.7%. Functional medicine optimal: <5.4% (minimizes cardiovascular risk per the ACCORD/ADVANCE trial data). Pre-diabetes range 5.7-6.4% represents an even greater clinical opportunity than fasting glucose — many patients in this range have been consuming an inflammatory diet for years. HbA1c can underestimate true glucose levels in patients with hemolytic anemia, iron deficiency, or B12 deficiency (abnormal red blood cell turnover).
Insulin (fasting): Not included in standard metabolic panels but essential for functional metabolic assessment. Standard labs report fasting insulin as “normal” up to 24-27 µIU/mL — a threshold that encompasses profound insulin resistance. Functional medicine optimal fasting insulin: <5 µIU/mL (associated with lowest cardiovascular risk and most favorable metabolic phenotype). HOMA-IR (fasting insulin × fasting glucose ÷ 405): optimal <1.5; insulin resistance >2.0; significant resistance >3.0. A patient with fasting glucose of 92 mg/dL and fasting insulin of 18 µIU/mL has significant insulin resistance (HOMA-IR 4.1) that is completely invisible on a standard CMP — and represents a major cardiovascular and diabetes risk that can be fully reversed with functional medicine intervention.
Liver enzymes (ALT, AST, GGT, alkaline phosphatase):
ALT (alanine aminotransferase): Standard range up to 56 U/L in many labs. Functional medicine optimal: <25 U/L for women, <30 U/L for men — consistent with the Kim 2008 Gastroenterology study defining optimal hepatic health. Elevations in the "normal" range (30-56 U/L) often indicate non-alcoholic fatty liver disease (NAFLD), which affects 30% of US adults and is directly driven by insulin resistance and fructose overconsumption.
GGT (gamma-glutamyl transferase): Standard range up to 65 U/L. GGT is a sensitive indicator of oxidative stress — it is the rate-limiting enzyme in extracellular glutathione recycling. Elevated GGT reflects: alcohol consumption, NAFLD, medication load (enzyme induction), heavy metal exposure, and most importantly — oxidative stress and depleted glutathione capacity. GGT above 30 U/L is associated with significantly increased cardiovascular mortality in prospective studies (Emdin 2001, Ruttmann 2005).
Alkaline phosphatase (ALP): Functional medicine interpretation: ALP below 70 U/L may indicate zinc deficiency (zinc is a cofactor for ALP activity — ALP is one of the most zinc-dependent enzymes in the body, and low ALP is a functional marker for zinc insufficiency). Standard ranges bottom out at 44 U/L but truly optimal ALP requires adequate zinc.
Kidney function (BUN, creatinine, eGFR): Standard eGFR “normal” above 60 mL/min/1.73m². Functional medicine flags early decline even within “normal” — eGFR trending from 90 to 75 to 65 over 3 years represents meaningful CKD progression requiring intervention, even if never below 60. BUN:creatinine ratio: >20 suggests prerenal azotemia (dehydration, low cardiac output, GI bleeding); <10 suggests liver dysfunction, malnutrition, or low protein intake. Cystatin C — a more accurate GFR marker not influenced by muscle mass — is particularly valuable in elderly patients or those with abnormal body composition where creatinine underestimates kidney dysfunction.
The Lipid Panel: What Standard Reporting Misses
Standard lipid panels (total cholesterol, LDL-C, HDL-C, triglycerides) provide incomplete cardiovascular risk information. Functional medicine lipid assessment includes advanced markers that more precisely characterize atherogenic risk:
LDL-C vs LDL-P vs ApoB: LDL-C measures the cholesterol content of LDL particles. LDL-P measures the number of LDL particles. ApoB measures the number of apolipoprotein B-containing atherogenic particles (LDL + VLDL + IDL + Lp(a)). In insulin resistance and metabolic syndrome, patients frequently have normal or low LDL-C with elevated small dense LDL particles — the “discordance” between LDL-C and LDL-P that predicts cardiovascular risk not captured by standard lipid panels. ApoB is now recognized by major cardiology societies as the most accurate single atherogenic biomarker. The Sachdeva 2009 meta-analysis found 75% of MI patients had admission LDL-C below 130 mg/dL — and these patients would have been considered “adequately treated” by standard cholesterol guidelines.
Triglycerides: Standard “normal” <150 mg/dL. Functional medicine optimal: <80 mg/dL. The triglyceride:HDL ratio is a powerful insulin resistance proxy — ratio >3.0 predicts insulin resistance with high sensitivity in Caucasian populations (McLaughlin 2005). Elevated triglycerides (>150 mg/dL) with low HDL (<40 men, <50 women) defines atherogenic dyslipidemia — the characteristic lipid pattern of metabolic syndrome, driven by insulin resistance and dietary carbohydrate, not dietary fat.
HDL-C: Standard “normal” >40 mg/dL for men, >50 mg/dL for women. Functional medicine optimal: >60 mg/dL for men, >70 mg/dL for women. Note: in very high HDL states (>90 mg/dL), HDL may actually be dysfunctional — large HDL particles with impaired reverse cholesterol transport in some genetic conditions (CETP deficiency) are paradoxically associated with increased cardiovascular risk.
Lipoprotein(a) — Lp(a): Not included in standard lipid panels. Lp(a) is an LDL particle with apolipoprotein(a) attached — it is 90% genetically determined and is not meaningfully modified by diet or exercise. Elevated Lp(a) (>50 mg/dL or >125 nmol/L) is present in approximately 20% of the population and is an independent risk factor doubling cardiovascular risk (Clarke 2009 NEJM n=165,000). Every patient should have Lp(a) measured once — it is the cardiovascular risk factor most commonly identified only after the first heart attack.
Coronary artery calcium (CAC) score: Not a blood test but essential to the functional cardiovascular assessment — CT scan quantifying calcified plaque in coronary arteries. CAC = 0 in a patient with elevated LDL confers very low 10-year event risk (MESA study: 3.5% 10-year event rate vs 8.5% for CAC >100). CAC > 100 in a patient with “normal” LDL identifies high-risk individuals for aggressive intervention. The MESA prospective study (n=6,814) demonstrated CAC reclassified risk in 23% of intermediate-risk patients — more than any blood biomarker alone.
The Thyroid Panel: Why TSH Alone Is Insufficient
Thyroid function assessment is one of the most contested areas between conventional and functional medicine interpretation:
TSH (thyroid stimulating hormone): Standard range: 0.5-4.5 mIU/L. Functional medicine optimal: 1.0-2.0 mIU/L. The upper end of the conventional TSH range is controversial — the National Academy of Clinical Biochemists stated that >95% of healthy euthyroid individuals have TSH below 2.5 mIU/L, suggesting TSH 2.5-4.5 may represent subclinical thyroid impairment in many patients. Progressive TSH elevation predicts future hypothyroidism: TSH 3.0-4.5 mIU/L confers 40-50% risk of hypothyroidism within 10 years in patients with positive TPO antibodies.
Free T4 (fT4) and free T3 (fT3): TSH alone measures pituitary feedback, not peripheral tissue thyroid hormone availability. Free T4 is the storage form; free T3 is the metabolically active form — requiring peripheral conversion by deiodinase enzymes (DIO1, DIO2). Standard labs: fT4 0.8-1.8 ng/dL, fT3 2.3-4.2 pg/mL. Functional medicine optimal: fT4 mid-normal (1.1-1.4 ng/dL), fT3 upper third of range (3.2-4.2 pg/mL). A patient with TSH of 2.8, normal fT4, but fT3 of 2.5 pg/mL has poor peripheral conversion — this is “low T3 syndrome” associated with fatigue, cold intolerance, cognitive dysfunction, and weight gain, and it is missed by TSH alone.
Reverse T3 (rT3): The inactive isomer of T3 — produced when T4 is converted to rT3 instead of active T3, typically during physiological stress, illness, caloric restriction, high cortisol, selenium deficiency, or inflammation. Elevated rT3 (>15 ng/dL) or low T3:rT3 ratio (<0.02) indicates functional hypothyroidism at the tissue level even with normal TSH and T4. This mechanism explains why many patients remain symptomatic on levothyroxine despite normalized TSH — they continue to over-convert T4 to inactive rT3.
Anti-TPO and anti-thyroglobulin antibodies: Essential for identifying autoimmune thyroid disease (Hashimoto’s) — which accounts for 90% of hypothyroidism in iodine-sufficient countries. Hashimoto’s can be present with normal TSH for years before overt hypothyroidism develops, yet already causing symptoms via inflammatory damage to thyroid tissue and systemic autoimmune activation. Standard labs: anti-TPO <35 IU/mL, anti-Tg <20 IU/mL. Any detectable elevation warrants functional medicine evaluation for gut permeability, gluten sensitivity, selenium deficiency, and other autoimmune drivers.
Inflammatory Markers: The Cardiovascular and Systemic Inflammation Assessment
hsCRP (high-sensitivity C-reactive protein): Standard labs report CRP as a binary “elevated/normal” — functional medicine uses hsCRP which quantifies low-level inflammation. Optimal: <0.7 mg/L. Low cardiovascular risk: <1.0 mg/L. Moderate risk: 1.0-3.0 mg/L. High risk: >3.0 mg/L (JUPITER trial criteria). The JUPITER trial (Ridker 2008 NEJM, n=17,802) demonstrated rosuvastatin reduced cardiovascular events by 44% in patients with elevated hsCRP and “normal” LDL — establishing hsCRP as an independent treatment indication beyond cholesterol. Non-cardiac causes of elevated hsCRP: infections, obesity, sleep apnea, depression, gut dysbiosis, smoking, and periodontal disease.
Homocysteine: An amino acid intermediate in the methionine cycle — elevated when B12, folate, B6, or riboflavin are deficient, or when methylation pathways are impaired (MTHFR variants). Optimal: <7.5 µmol/L. Standard "normal" upper limit is 10-15 µmol/L in most labs — but Wald 2002 meta-analysis (BMJ, n=5,073) demonstrated each 5 µmol/L increase in homocysteine associated with 1.4× increased ischemic heart disease risk. Elevated homocysteine damages vascular endothelium, promotes atherosclerotic plaque formation, impairs nitric oxide synthesis, and increases thrombosis risk.
Uric acid: Standard labs flag above 7-8 mg/dL (gout threshold). Functional medicine: optimal <5.5 mg/dL for men, <4.0 mg/dL for women. Uric acid above 5.5 mg/dL is independently associated with hypertension, insulin resistance, kidney disease, and cardiovascular risk — driven by fructose metabolism (fructose uniquely consumes ATP during hepatic metabolism, generating AMP → uric acid via the purine degradation pathway). Elevated uric acid is a biomarker of excess fructose/carbohydrate intake and early metabolic syndrome.
Ferritin (as inflammation marker): In addition to iron storage, ferritin is an acute phase reactant. Ferritin >200 ng/mL in women or >300 ng/mL in men without known iron overload suggests chronic inflammation. Ferritin above 500 ng/mL warrants investigation for hemochromatosis (HFE gene mutation), adult-onset Still’s disease, macrophage activation syndrome, or significant hepatic/inflammatory pathology. The paradox: elevated ferritin can mean either iron overload OR severe inflammation with iron sequestration — clinical context and transferrin saturation distinguish these.
Hormone Panels: Functional Reference Ranges
Vitamin D (25-OH cholecalciferol): Standard “sufficient”: >30 ng/mL. Functional medicine optimal: 50-80 ng/mL. Below 30 ng/mL: deficiency with measurable immune, bone, and cardiovascular risk. The Holick 2011 and Heaney 2011 data demonstrate most physiological vitamin D functions (immune modulation, muscle function, cancer prevention) require levels in the 40-80 ng/mL range. Above 100 ng/mL: potential hypercalcemia risk. D3 (cholecalciferol) supplementation with K2 (MK-7 form — directs calcium to bone, not arteries) is the functional medicine standard.
DHEA-S (dehydroepiandrosterone sulfate): The most abundant circulating steroid — a precursor to sex hormones and an independent immunological and neurological hormone. Peak at age 25-30, declining 2% per year. Functional medicine optimal: age-appropriate mid-to-upper reference range. Below the 25th percentile for age: early HPA axis aging, associated with increased cardiovascular mortality (Barrett-Connor 1986 NEJM), cognitive decline, immune senescence, and poor stress resilience. DHEA replacement (micronized DHEA 5-25mg/day, tested and titrated) is one of the most underutilized functional medicine interventions for HPA dysfunction and longevity optimization.
Testosterone (total and free): Standard labs report only total testosterone; free testosterone (the biologically active fraction not bound to SHBG) is more clinically relevant. In men: total testosterone optimal 500-900 ng/dL (many labs normal ≥300 ng/dL — but symptoms of hypogonadism are common at 300-400 ng/dL). Free testosterone optimal >15 ng/dL (Bhasin 2010 consensus). SHBG elevation (from thyroid disease, liver dysfunction, estrogen, aging) reduces free testosterone even with normal total testosterone. In women: testosterone 15-70 ng/dL total; free testosterone should be mid-to-upper range for age.
Estradiol (women): Highly cycle-dependent — must be interpreted in context of menstrual phase. Functional medicine patterns: luteal phase progesterone:estradiol ratio <100:1 (pg/mL units) suggests estrogen dominance or progesterone insufficiency — a pattern associated with PMS, endometriosis, fibrocystic breast disease, and fibroids. Perimenopausal women: declining estradiol with inadequate progesterone produces the "estrogen dominance" pattern paradoxically — as progesterone falls faster than estrogen early in perimenopause.
Micronutrients: The Often-Skipped Nutritional Panel
Standard medical workups rarely include comprehensive nutritional status assessment. Yet NHANES data consistently demonstrates widespread micronutrient insufficiency:
Magnesium (RBC, not serum): Serum magnesium is maintained in a narrow range by bone resorption and renal reabsorption — it can appear normal even when intracellular magnesium (reflecting total body stores) is significantly depleted. RBC magnesium (optimal >5.5 mg/dL) reflects intracellular stores more accurately. The NHANES III survey found 48% of Americans consume less than the RDA for magnesium. Magnesium is required for over 300 enzymatic reactions — deficiency contributes to insulin resistance, hypertension, cardiac arrhythmia, muscle cramps, insomnia, anxiety, and migraine.
Zinc (plasma or RBC): Serum zinc fluctuates with meal timing and acute phase responses — plasma zinc is more reliable than serum. Optimal plasma zinc: 90-130 µg/dL. Low zinc is associated with reduced testosterone (Prasad 1996 Nutrition), impaired immune function, poor wound healing, anosmia, and depression. Functional alkaline phosphatase (discussed above) provides an additional functional zinc marker.
Omega-3 index (HS-Omega-3 Index): Measures EPA + DHA as percentage of total RBC membrane fatty acids. Optimal: ≥8%. Below 4%: high cardiovascular risk (Harris and Von Schacky 2004 Preventive Medicine demonstrated 10× increased sudden cardiac death risk at <3.5% vs ≥8%). The omega-3 index directly predicts cardiovascular, neurocognitive, and inflammatory outcomes more accurately than dietary questionnaire assessment of fish intake.
CoQ10 (plasma ubiquinol): Particularly relevant in patients taking statin medications — statins block the mevalonate pathway that produces both cholesterol AND CoQ10 synthesis. A 2007 meta-analysis demonstrated statins reduce plasma CoQ10 by 40-50%. Optimal plasma CoQ10: >1.0 µg/mL. Low CoQ10 contributes to statin myopathy, exercise intolerance, and mitochondrial dysfunction — the most underappreciated statin side effect mechanism.
Reading Your Labs: Pattern Recognition Across Multiple Markers
The most powerful functional medicine skill in lab interpretation is recognizing cross-marker patterns that tell a coherent biological story:
The insulin resistance pattern: Fasting glucose 90-100 mg/dL + fasting insulin >8 µIU/mL + triglycerides >100 mg/dL + HDL <55 mg/dL + waist circumference elevated + blood pressure trending upward. Each marker may be individually "normal" — together they paint a clear picture of advancing metabolic syndrome requiring immediate lifestyle intervention.
The methylation impairment pattern: Elevated homocysteine (>10 µmol/L) + low-normal B12 (200-400 pg/mL) + elevated MCV (96-100 fL) + elevated RDW + low-normal folate + MTHFR C677T heterozygous or homozygous. This pattern drives cardiovascular risk, cognitive decline, neural tube defects in pregnancy, mood disorders, and accelerated epigenetic aging — and responds dramatically to targeted methylation support.
The functional hypothyroidism pattern: TSH 2.5-4.5 + fT3 low-normal (2.3-2.8 pg/mL) + elevated anti-TPO antibodies + elevated cholesterol (thyroid regulates cholesterol metabolism) + elevated CRP (autoimmune inflammation) + ferritin below 70 ng/mL (thyroid requires iron). Symptoms: fatigue, cold intolerance, weight gain, constipation, hair thinning, cognitive slowing. Often treated as “within normal limits” while the patient continues to deteriorate.
The adrenal/HPA depletion pattern: Low DHEA-S (below 100 µg/dL in women, below 200 µg/dL in men under 50) + low-normal fasting cortisol + low vitamin D + elevated hsCRP + low testosterone + symptoms of fatigue, poor stress tolerance, recurrent infections, and sleep dysfunction. This HPA depletion pattern is increasingly common and responds to adaptogen support, DHEA restoration, and lifestyle pacing.
Functional Lab Interpretation at The Private Practice
Dr. Biernacki provides a comprehensive functional medicine laboratory evaluation that goes well beyond a standard annual physical — including advanced metabolic markers (fasting insulin, HOMA-IR, Lp(a), ApoB, hsCRP, homocysteine), full thyroid panel with antibodies, sex hormone panel with DHEA-S, 25-OH vitamin D, RBC magnesium, omega-3 index, and additional markers based on clinical presentation.
The results are interpreted in clinical context using functional reference ranges — and translated into a personalized intervention protocol rather than simply a list of abnormal values. If your annual labs have been coming back “normal” but you don’t feel normal, a functional medicine lab interpretation may identify the pattern that explains your symptoms. Call (810) 206-1402 to schedule a comprehensive functional medicine laboratory evaluation.
Frequently Asked Questions About Functional Lab Interpretation
Q: Why does my doctor say my labs are normal when I still feel terrible?
A: Standard reference ranges are designed to catch frank disease — not optimize function. A TSH of 4.0, fasting insulin of 15, ferritin of 18, 25-OHD of 28 ng/mL, and RBC magnesium of 4.8 are all technically “within reference range” by most laboratory standards — yet each represents significant suboptimal function that functional medicine evaluates and addresses. Additionally, standard workups omit key markers entirely (fasting insulin, Lp(a), omega-3 index, homocysteine, RBC magnesium, full thyroid panel) that could explain symptoms.
Q: What is the difference between serum magnesium and RBC magnesium?
A: Serum magnesium measures the magnesium circulating in blood plasma — approximately 1% of total body magnesium. The body maintains serum magnesium in a tight range (0.75-0.95 mmol/L) through bone resorption and renal reabsorption, even when intracellular stores are severely depleted. RBC magnesium measures the magnesium inside red blood cells — a more accurate proxy for intracellular (tissue) magnesium stores. Serum magnesium can appear normal while RBC magnesium is significantly low — explaining why many patients with magnesium deficiency symptoms (cramps, insomnia, anxiety, migraine) have “normal” magnesium on standard testing.
Q: Is it dangerous to have vitamin D levels above 50 ng/mL?
A: No, at levels below 100 ng/mL. Vitamin D toxicity (hypercalcemia) does not occur below 150-200 ng/mL in the absence of granulomatous disease (sarcoidosis, tuberculosis) or primary hyperparathyroidism. The Endocrine Society practice guidelines acknowledge safety up to 100 ng/mL. Multiple large prospective studies and RCTs demonstrate superior immune, cardiovascular, and oncological outcomes at levels in the 50-80 ng/mL range. The concern about “dangerously high vitamin D” from levels of 50-80 ng/mL is not supported by the evidence and prevents patients from achieving optimal levels.
Q: How often should functional medicine labs be checked?
A: Baseline comprehensive panel at the start of functional medicine care, with follow-up at 3-6 months to assess response to interventions. Ongoing: fasting insulin, thyroid panel, and inflammatory markers (hsCRP, homocysteine) annually or semi-annually depending on clinical status. Micronutrients (vitamin D, B12, magnesium) every 6 months while supplementing until optimal levels are established, then annually once stable. CAC score: every 3-5 years in appropriate cardiovascular risk assessment (generally after age 40-45 in intermediate-risk patients). DUTCH cortisol testing: when clinical symptoms of HPA dysfunction emerge or every 1-2 years in patients with chronic stress and adrenal concerns.